Compare Heron Therapeutics Inc (HRTX) vs iShares iBoxx $ Inv Grade Corporate Bond ETF (LQD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs iShares iBoxx $ Inv Grade Corporate Bond ETF — how do they compare? Heron Therapeutics Inc trades at $0.35 (market cap $61.47M), while iShares iBoxx $ Inv Grade Corporate Bond ETF trades at $106.23. Which is the better fit depends on your goals.
| HRTX | LQD | |
|---|---|---|
Market Cap | $61.47M | — |
Sector | Health | — |
52-Week High | $1.49 | $112.91 |
52-Week Low | $0.32 | $105.96 |
Enterprise Value | $168.21M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.3152, down 4.54% today, amid bearish technical signals and mixed earnings. The stock shows a high gross margin of 70.07% but negative net income margins, with Q2 2026 missing revenue and EPS estimates. Recent news highlights patent litigation developments and quarterly results falling short of expectations, contributing to investor caution.
The outlook remains challenged by persistent losses and operational cash burn, though analyst consensus is strongly bullish with 94.74% buy ratings. Key risks include execution on product sales, competitive pressures, and reliance on financing activities to sustain operations amid negative profitability.
LQD, the iShares iBoxx $ Investment Grade Corporate Bond ETF, trades at $106.335, up 0.35% today, while technical indicators signal a bearish trend with moving averages and key oscillators in sell or neutral territory. The ETF has declared several dividends for 2026, with payments scheduled through August, reflecting its income-focused strategy amid fluctuating bond markets driven by inflation fears and geopolitical tensions.
The outlook for LQD is cautious due to bearish technicals and macroeconomic pressures like rising oil prices and potential Fed rate hikes, which could pressure corporate bond yields. Investors may find value in its investment-grade corporate debt exposure for diversification, but must monitor interest rate volatility and economic data closely for risks to fixed income returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About iShares iBoxx $ Inv Grade Corporate Bond ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index, and it will invest at least 90% of its assets in fixed income securities of the types included in the underlying index that the advisor believes will help the fund track the underlying index. The underlying index is designed to provide a broad representation of the US dollar-denominated liquid investment-grade corporate bond market.
Read more on LQD →
